Terms: = Prostate cancer AND ETV5, P41161, 2119, ENSG00000244405, ERM
51 results:
1. Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer.
Koelker M; Labban M; Frego N; Ye J; Lipsitz SR; Hubbell HT; Edelen M; Steele G; Salinas K; Meyer CP; Makanjuola J; Moore CM; Cole AP; Kibel AS; Trinh QD
Prostate; 2024 Jan; 84(1):47-55. PubMed ID: 37710385
[TBL] [Abstract] [Full Text] [Related]
2. Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.
Mavura Y; Song H; Xie J; Tamayo P; Mohammed A; Lawal AT; Bello A; Ibrahim S; Faruk M; Huang FW
Prostate; 2023 Apr; 83(5):395-402. PubMed ID: 36598071
[TBL] [Abstract] [Full Text] [Related]
3. Transcriptomes of prostate cancer with TMPRSS2:ERG and Other ETS Fusions.
Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
[TBL] [Abstract] [Full Text] [Related]
4. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract] [Full Text] [Related]
5. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract] [Full Text] [Related]
6. The ETS transcription factor etv5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
[TBL] [Abstract] [Full Text] [Related]
7. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract] [Full Text] [Related]
8. Pseudogene Associated Recurrent Gene Fusion in prostate cancer.
Chakravarthi BV; Dedigama-Arachchige P; Carskadon S; Sundaram SK; Li J; Wu KH; Chandrashekar DS; Peabody JO; Stricker H; Hwang C; Chitale DA; Williamson SR; Gupta NS; Navone NM; Rogers C; Menon M; Varambally S; Palanisamy N
Neoplasia; 2019 Oct; 21(10):989-1002. PubMed ID: 31446281
[TBL] [Abstract] [Full Text] [Related]
9. Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.
Segalés L; Juanpere N; Lorenzo M; Albero-González R; Fumadó L; Cecchini L; Bellmunt J; Lloreta-Trull J; Hernández-Llodrà S
Virchows Arch; 2019 Oct; 475(4):457-466. PubMed ID: 31016435
[TBL] [Abstract] [Full Text] [Related]
10. Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors.
Currie SL; Warner SL; Vankayalapati H; Liu X; Sharma S; Bearss DJ; Graves BJ
SLAS Discov; 2019 Jan; 24(1):77-85. PubMed ID: 30204534
[TBL] [Abstract] [Full Text] [Related]
11. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract] [Full Text] [Related]
12. ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain.
Currie SL; Doane JJ; Evans KS; Bhachech N; Madison BJ; Lau DKW; McIntosh LP; Skalicky JJ; Clark KA; Graves BJ
J Mol Biol; 2017 Oct; 429(20):2975-2995. PubMed ID: 28728983
[TBL] [Abstract] [Full Text] [Related]
13. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive Determination of prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.
Torres A; Alshalalfa M; Tomlins SA; Erho N; Gibb EA; Chelliserry J; Lim L; Lam LLC; Faraj SF; Bezerra SM; Davicioni E; Yousefi K; Ross AE; Netto GJ; Schaeffer EM; Lotan TL
J Mol Diagn; 2017 May; 19(3):475-484. PubMed ID: 28341589
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
[TBL] [Abstract] [Full Text] [Related]
16. Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness.
Bizzarro V; Belvedere R; Migliaro V; Romano E; Parente L; Petrella A
Cell Adh Migr; 2017 May; 11(3):247-260. PubMed ID: 27834582
[TBL] [Abstract] [Full Text] [Related]
17. An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in prostate cancer.
Kedage V; Selvaraj N; Nicholas TR; Budka JA; Plotnik JP; Jerde TJ; Hollenhorst PC
Cell Rep; 2016 Oct; 17(5):1289-1301. PubMed ID: 27783944
[TBL] [Abstract] [Full Text] [Related]
18. miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression.
Choi N; Park J; Lee JS; Yoe J; Park GY; Kim E; Jeon H; Cho YM; Roh TY; Lee Y
Oncotarget; 2015 Sep; 6(27):23533-47. PubMed ID: 26124181
[TBL] [Abstract] [Full Text] [Related]
19. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract] [Full Text] [Related]
20. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract] [Full Text] [Related]
[Next]
